

TREATMENT NOTE TEMPLATE/EMR (Knee)

Smart Tip 190

iovera[®]

(This document includes suggested language that can be used as a guide to supplement your own EMR documentation.)

PROCEDURE: (check all that apply)

Ultrasound ☐ Right ☐ Left ☐ Bilateral of lower extremity from groin to mid-calf to localize the relevant peripheral nerves supplying sensation to the anterior knee.

Destruction by neurolytic agent (iovera[®] cryoanalgesia)

☐ Right ☐ Left ☐ Bilateral knee peripheral nerves under ultrasound guidance.

PRIOR TO PROCEDURE: (check all that apply)

History and physical/applicable labs reviewed. ☐ Yes ☐ No

Identify changes and contraindications. ☐ Yes ☐ No

Details of the procedure including the risk, benefits, alternatives to treatment, and possible complications were reviewed with patient. ☐ Yes ☐ No

Informed written consent was obtained. ☐ Yes ☐ No

RIGHT KNEE

Pre-treatment pain score:

0 1 2 3 4 5 6 7 8 9 10

LEFT KNEE

Pre-treatment pain score:

0 1 2 3 4 5 6 7 8 9 10

PROCEDURE PREPARATION:

- ☐ Patient was placed in supine position.

Target Nerves were identified using:

☐ Anatomical Landmarks ☐ Ultrasound ☐ Nerve Stimulator

The patient's leg was positioned:

☐ Flat ☐ Wedge

- ☐ A mark was made [__mm] proximal to the medial pole of the patella on the mid-thigh to mark a starting point for ultrasound scanning.
- ☐ Ultrasound guidance was then used to confirm the location of the peripheral nerves responsible for anterior knee innervation and their location was marked on the overlying skin.
- ☐ After the nerves are located a skin indentation is made with a blunt object to mark the needle insertion site.
- ☐ Patient's skin was shaved if necessary.
- ☐ Patient's skin was cleansed using [Antiseptic] on the [Treatment Areas].
- ☐ The skin insertion site was anesthetized using [Topical Anesthetic].
- ☐ A skin wheel was created at each treatment site with [Needle Type] and infiltrated approximately [Amount/Type of Anesthetic].
- ☐ [Needle Type] was used to enlarge the treatment insertion site on the skin.
- ☐ Using ultrasound guidance, infiltrated approximately [Amount/Type of Anesthetic] using a [Needle Type] to area of the nerve being treated.

DESCRIPTION OF PROCEDURE:

- ☐ After the anesthetic was administered, the [Smart Tip] cryoneurolysis needle was inserted into the treatment site using ultrasound guidance [Treatment Lines/All Locations], and the treatment was initiated. The treatment duration was [X] seconds per cycle.

Right Knee Treatment

Zone of influence	Nerve	Nerve depth on ultrasound	Thigh level measured	Number of times site treated
Proximal medial knee pain				
Anterior knee pain				
Proximal lateral knee pain				
Distal medial knee pain				
Distal lateral knee pain				

Left Knee Treatment

Zone of influence	Nerve	Nerve depth on ultrasound	Thigh level measured	Number of times site treated
Proximal medial knee pain				
Anterior knee pain				
Proximal lateral knee pain				
Distal medial knee pain				
Distal lateral knee pain				

- ☐ At the termination of the treatment, the cryoneurolysis needle was removed.
- ☐ Patient's skin was cleansed and the treatment site was covered with a bandage.
- ☐ Patient tolerated procedure [Description of how the patient tolerated the procedure].
- ☐ The patient was instructed to stand and mobilize the knee joint.
- ☐ Post treatment assessment performed and discharge instructions given to the patient.

Treatment Start Time: _____ Treatment Stop Time: _____

RIGHT KNEE

Post-treatment pain score:

0 1 2 3 4 5 6 7 8 9 10

LEFT KNEE

Post-treatment pain score:

0 1 2 3 4 5 6 7 8 9 10

Indication

The iovera® system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. The iovera® system is not indicated for treatment of central nervous system tissue. The iovera® system's 1x90° Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator.

Contraindications

The iovera® system is contraindicated for use in patients with the following:

- Cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and open and/or infected wounds at or near the treatment site

Potential Complications

As with any surgical treatment that uses needle-based therapy and local anesthesia, there is a potential for site-specific reactions, including, but not limited to:

- Ecchymosis, edema, erythema, local pain and/or tenderness, and localized dysesthesia

Proper use of the device as described in the User Guide can help reduce or prevent the following complications:

- At the treatment site(s): injury to the skin related to application of cold or heat, hyper- or hypopigmentation, and skin dimpling
- Outside the treatment site(s): loss of motor function

©2020 Pacira BioSciences, Inc. All rights reserved. iovera® is a trademark of Pacira CryoTech, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc.

PP-IO-US-0409 11/20 MKT-5533 Rev A

PACIRA
BIOSCIENCES, INC.

www.iovera.com